Short answer
Edgewise Therapeutics, Inc. (EWTX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$41M
- −19.2% YoY · −12.6% QoQ
- EPS (diluted)
- −$0.38
- −2.7% YoY · −11.8% QoQ
Source: XBRL data from the Edgewise Therapeutics, Inc. (EWTX) Q3 2025 10-Q on SEC EDGAR. USD.
Edgewise Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Initiated Phase 1 trial for EDG-15400 in Sept 2025, expanding clinical development pipeline
- Material update: Net loss $117.6M YTD Sept 2025, accumulated deficit $496.2M, reflecting increased R&D and operational expenses
- Regulatory risk: FDA comparability analysis requirement for manufacturing process changes may delay trials and approvals
- Operational risk: Reliance on third-party manufacturers risks supply delays impacting clinical trial timelines and commercialization
- Financial risk: Cash $563.3M as of Sept 30, 2025, funded by $187.1M April 2025 equity offering; sufficient for 12 months but additional capital needed beyond that
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edgewise Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.